medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2013, Number 01-02

<< Back Next >>

Medicina & Laboratorio 2013; 19 (01-02)

18F-FDG-PET-CT: rational use in diagnosis and staging of oncologic diseases

Vega GIF, Ramírez FJC, Osorio AGD, Quintero ÁFM, Patiño RA, Vivas BI

Language: Spanish
References: 66
Page: 69-88
PDF size: 1542.63 Kb.


ABSTRACT

Molecular imaging techniques evaluate intracellular metabolic processes; currently, these techniques are an effective tool for cancer diagnosis. The most important and widely used technique is PET-CT (positron-emission tomography and computed tomography), wherein PET obtains a metabolic image of the tumor, a way as to determine its viability, while CT enables an accurate anatomical location of the lesion. Hence, PET-CT is a test with high diagnostic performance in oncology, allowing early detection, staging and assessment of response to therapy in patients with malignancies. This review article aims to describe the technical and biological fundamentals of PET-CT, and its rational use in oncologic practice, especially during early detection of cancer and staging of the disease.


REFERENCES

  1. Gillings N. Radiotracers for positron emission tomography imaging. MAGMA 2012. [Ep z ub ahead of print].

  2. Schiepers C, Dahlbom M. Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging. Eur Radiol 2011; 21: 548-554.

  3. Krause BJ, Schwarzenbock S, Souvatzoglou M. FDG PET and PET/CT. Recent Results Cancer Res 2013; 187: 351-369.

  4. Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF. Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting. Anticancer Res 2013; 33: 13-20.

  5. Cherry SR. In vivo molecular and genomic imaging: new challenges for imaging physics. Phys Med Biol 2004; 49: R13-48.

  6. Townsend DW, Cherry SR. Combining anatomy and function: the path to true image fusion. Eur Radiol 2001; 11: 1968-1974.

  7. Townsend DW. Multimodality imaging of structure and function. Phys Med Biol 2008; 53: R1-R39.

  8. Vega IF, Graef A, García JC, Ornelas M. Nuevas Modalidades de Imagen: PET-CT. Med Sur 2005; 12: 11- 25.

  9. Alauddin MM. Positron emission tomography (PET) imaging with (18)F-based radiotracers. Am J Nucl Med Mol Imaging 2012; 2: 55-76.

  10. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology 2007; 242: 360-385.

  11. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.

  12. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927; 8: 519-530.

  13. Czernin J, Benz MR, Allen-Auerbach MS. PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination. Eur J Radiol 2010; 73: 470-480.

  14. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro- 2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189: 847-850.

  15. Grammaticos P, Datseris I, Gerali S, Papantoniou V, Valsamaki P, Boundas D. [Indications and instructions to patients for a positron emission tomography- PET scan. The importance of the hybridic PET/ CT-computerised tomography scan and which specialty should be responsible for its function]. Hell J Nucl Med 2007; 10: 125-128.

  16. Larson SM, Schwartz LH. 18F-FDG PET as a candidate for “qualified biomarker”: functional assessment of treatment response in oncology. J Nucl Med 2006; 47: 901-903.

  17. Hartwell L, Mankoff D, Paulovich A, Ramsey S, Swisher E. Cancer biomarkers: a systems approach. Nat Biotechnol 2006; 24: 905-908.

  18. Pfannenberg AC, Aschoff P, Brechtel K, Muller M, Klein M, Bares R, et al. Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging. Br J Radiol 2007; 80: 437-445.

  19. Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol 2000; 27: 683-687.

  20. International Atomic Energy Agency. Appropriate use of FDG-PET for the management of cancer patients. IAEA human health series. Vienna: IAEA; 2010.

  21. Chen YK, Ding HJ, Su CT, Shen YY, Chen LK, Liao AC, et al. Application of PET and PEt/CT imaging for cancer screening. Anticancer Res 2004; 24: 4103-4108.

  22. Han A, Xue J, Hu M, Zheng J, Wang X. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary. Cancer Epidemiol 2012; 36: 470-475.

  23. Kim SK, Allen-Auerbach M, Goldin J, Fueger BJ, Dahlbom M, Brown M, et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med 2007; 48: 214-220.

  24. Tournoy KG, Keller SM, Annema JT. Mediastinal staging of lung cancer: novel concepts. Lancet Oncol 2012; 13: e221-229.

  25. Serrano OK, Chaudhry MA, Leach SD. The role of PET scanning in pancreatic cancer. Adv Surg 2010; 44: 313-325.

  26. Shrikhande SV, Barreto SG, Goel M, Arya S. Multimodality imaging of pancreatic ductal adenocarcinoma: a review of the literature. HPB (Oxford) 2012; 14: 658-668.

  27. Chen YH, Yang XM, Li SS, Wang YH, He JJ, Yang YD, et al. Value of fused positron emission tomography CT in detecting primaries in patients with primary unknown cervical lymph node metastasis. J Med Imaging Radiat Oncol 2012; 56: 66-74.

  28. Pereira G, Silva JC, Monteiro E. Positron emission tomography in the detection of occult primary head and neck carcinoma: a retrospective study. Head Neck Oncol 2012; 4: 34.

  29. Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol 2009; 70: 382-392.

  30. Barber TW, Duong CP, Leong T, Bressel M, Drummond EG, Hicks RJ. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med 2012; 53: 864-871.

  31. Gregory DL, Hicks RJ, Hogg A, Binns DS, Shum PL, Milner A, et al. Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data. J Nucl Med 2012; 53: 1007-1015.

  32. Xu G, Zhao L, He Z. Performance of Whole-Body PET/ CT for the Detection of Distant Malignancies in Various Cancers: A Systematic Review and Meta-Analysis. J Nucl Med 2012; 53: 1847-1854.

  33. Lin M, Ambati C. The management impact of clinically significant incidental lesions detected on staging FDG PET-CT in patients with non-small cell lung cancer (NSCLC): an analysis of 649 cases. Lung Cancer 2012; 76: 344-349.

  34. Wu Y, Li P, Zhang H, Shi Y, Wu H, Zhang J, et al. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients. Int J Cancer 2013; 132: E37-47.

  35. Yang WF, Tan GZ, Fu Z, Yu JM. [Evaluation of the diagnostic value of (18)F-FDG PET-CT and enhanced CT for staging of lymph node metastasis in non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi 2009; 31: 925-928.

  36. Brennan ME, Houssami N. Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer. Breast 2012; 21: 112-123.

  37. Garami Z, Hascsi Z, Varga J, Dinya T, Tanyi M, Garai I, et al. The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan. Eur J Surg Oncol 2012; 38: 31-37.

  38. Riegger C, Herrmann J, Nagarajah J, Hecktor J, Kuemmel S, Otterbach F, et al. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging 2012; 39: 852-863.

  39. Beasley GM, Parsons C, Broadwater G, Selim MA, Marzban S, Abernethy AP, et al. A multicenter prospective evaluation of the clinical utility of F-18 FDGPET/ CT in patients with AJCC stage IIIB or IIIC extremity melanoma. Ann Surg 2012; 256: 350-356.

  40. Bronstein Y, Ng CS, Rohren E, Ross MI, Lee JE, Cormier J, et al. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. AJR Am J Roentgenol 2012; 198: 902-908.

  41. Pleiss C, Risse JH, Biersack HJ, Bender H. Role of FDG-PET in the assessment of survival prognosis in melanoma. Cancer Biother Radiopharm 2007; 22: 740-747.

  42. Castaldi P, Rufini V, Bussu F, Micciche F, Dinapoli N, Autorino R, et al. Can “early” and “late”18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy? Radiother Oncol 2012; 103: 63-68.

  43. Kurien G, Hu J, Harris J, Seikaly H. Cost-effectiveness of positron emission tomography/computed tomography in the management of advanced head and neck cancer. J Otolaryngol Head Neck Surg 2011; 40: 468-472.

  44. Xu GZ, Guan DJ, He ZY. (18)FDG-PET/CT for detecting distant metastases and second primary cancers in patients with head and neck cancer. A meta-analysis. Oral Oncol 2011; 47: 560-565.

  45. de Wit M, Brenner W, Hartmann M, Kotzerke J, Hellwig D, Lehmann J, et al. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol 2008; 19: 1619-1623.

  46. Huddart RA, O’Doherty MJ, Padhani A, Rustin GJ, Mead GM, Joffe JK, et al. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 2007; 25: 3090-3095.

  47. Aide N, Cappele O, Bottet P, Bensadoun H, Regeasse A, Comoz F, et al. Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 2003; 30: 1236-1245.

  48. Le Moulec S, Carassou P, Billemont B, Massard C, Vedrine L, Gontier E, et al. Prospective evaluation of FDG-PET/CT in patients with advanced RCC treated with antiangiogenic therapies. In: Oncology ASoC ed. ASCO meeting Genitourinary Cancers Symposium 2010.

  49. Park W, Park YJ, Huh SJ, Kim BG, Bae DS, Lee J, et al. The usefulness of MRI and PET imaging for the detection of parametrial involvement and lymph node metastasis in patients with cervical cancer. Jpn J Clin Oncol 2005; 35: 260-264.

  50. Son H, Kositwattanarerk A, Hayes MP, Chuang L, Rahaman J, Heiba S, et al. PET/CT evaluation of cervical cancer: spectrum of disease. Radiographics 2010; 30: 1251-1268.

  51. Karaosmanoglu AD, Blake MA. Applications of PET Campuzano-Maya G. Vega-González IF, Ramírez-Fontalvo JC, Osorio-Arenas GD, Quintero Álvarez FM, Patiño-Rengifo A, Vivas-Bonilla I. Medicina & Laboratorio: Programa de Educación Médica Continua Certificada Universidad de Antioquia, Edimeco CT in patients with esophageal cancer. Diagn Interv Radiol 2012; 18: 171-182.

  52. Kosugi C, Saito N, Murakami K, Ochiai A, Koda K, Ono M, et al. Positron emission tomography for preoperative staging in patients with locally advanced or metastatic colorectal adenocarcinoma in lymph node metastasis. Hepatogastroenterology 2008; 55: 398-402.

  53. Rappeport ED, Loft A, Berthelsen AK, von der Recke P, Larsen PN, Mogensen AM, et al. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol 2007; 48: 369-378.

  54. Paes FM, Kalkanis DG, Sideras PA, Serafini AN. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics 2010; 30: 269-291.

  55. Pinilla I, Gomez-Leon N, Del Campo-Del Val L, Hernandez- Maraver D, Rodriguez-Vigil B, Jover-Diaz R, et al. Diagnostic value of CT, PET and combined PET/ CT performed with low-dose unenhanced CT and fulldose enhanced CT in the initial staging of lymphoma. Q J Nucl Med Mol Imaging 2011; 55: 567-575.

  56. Wu LM, Chen FY, Jiang XX, Gu HY, Yin Y, Xu JR. 18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: a systematic review and meta-analysis. Eur J Radiol 2012; 81: 303-311.

  57. Alvarez Paez AM, Nogueiras Alonso JM, Serena Puig A. 18F-FDG-PET/CT in lymphoma: two decades of experience. Rev Esp Med Nucl Imagen Mol 2012; 31: 340-349.

  58. Harkirat S, Anand S, Jacob M. Forced diuresis and dual-phase F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers. Indian J Radiol Imaging 2010; 20: 13-19.

  59. Jensen TK, Holt P, Gerke O, Riehmann M, Svolgaard B, Marcussen N, et al. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/ computed axial tomography and magnetic resonance imaging: correlation with histopathology. Scand J Urol Nephrol 2011; 45: 122-128.

  60. Kibel AS, Dehdashti F, Katz MD, Klim AP, Grubb RL, Humphrey PA, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/ computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 2009; 27: 4314- 4320.

  61. De Iaco P, Musto A, Orazi L, Zamagni C, Rosati M, Allegri V, et al. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. Eur J Radiol 2011; 80: e98-103.

  62. Rakheja R, Makis W, Skamene S, Nahal A, Brimo F, Azoulay L, et al. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients. AJR Am J Roentgenol 2012; 198: 1409-1416.

  63. Borbely K, Wintermark M, Martos J, Fedorcsak I, Bognar L, Kasler M. The pre-requisite of a second- generation glioma PET biomarker. J Neurol Sci 2010; 298: 11-16.

  64. Bertagna F, Motta F, Fisogni S, Lena MS, Lucchini S, Giubbini R. Absence of urine production due to renal failure enables clear visualization of primary urinary bladder carcinoma on 18F-FDG PET/CT. Clin Nucl Med 2012; 37: 611-613.

  65. Reuter S, Rahbar K, Busch V, Hillebrand U, Velden J, Pavenstadt H, et al. Acute renal failure due to primary bilateral renal large B-cell lymphoma: diagnostics and follow-up by FDG-PET/CT. Clin Nucl Med 2009; 34: 722-724.

  66. Rozalli FI, Chua SC, Green DJ. Elucidation of acute renal failure due to recurrent non-Hodgkin lymphoma by F-18 FDG PET/CT. Clin Nucl Med 2008; 33: 201-203.




2020     |     www.medigraphic.com